Thiogenesis Therapeutics, Corp. News Releases

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

Wed, 17 Jun 2026 08:00:00 -0400

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life...

Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million

Wed, 03 Jun 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of...

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Mon, 01 Jun 2026 14:49:00 -0400

San Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, today announced that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement (the "Offering") (see the Company's news release dated May 11, 2026) from 16 million to approximately...

Thiogenesis Announces Non-Brokered Private Placement

Mon, 11 May 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million.This Offering is subject to...

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

Thu, 16 Apr 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada.Presentation Details:Date: Wednesday, April 22, 2026Time:...

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Mon, 02 Feb 2026 09:00:00 -0500

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University...

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Fri, 23 Jan 2026 09:00:00 -0500

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improvement San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients...

Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

Tue, 13 Jan 2026 09:00:00 -0500

San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that an abstract outlining preliminary results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in the EU has been...

Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Mon, 05 Jan 2026 09:00:00 -0500

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome Trial San Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United...

Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis

Mon, 24 Nov 2025 09:00:00 -0500

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosing San Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of...